<DOC>
	<DOCNO>NCT01691014</DOCNO>
	<brief_summary>The rationale study explore development antibody TNF-α block agent associate reduced clinical effect/worsened clinical outcome . An important aspect study carry exploratory analysis immunogenicity 4 recommend TNF-α blocker treatment RA Denmark , use cell-based assay .</brief_summary>
	<brief_title>Formation Antibodies Subsequent Prediction Clinical Response Patients With Rheumatoid Arthritis Treated With Four TNF Blocking Agents</brief_title>
	<detailed_description>sample</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Subject fulfils criterion Rheumatoid Arthritis ( RA ) accord ACR EULAR criterion . Subjects plan start treatment ADA , ETA , CER IFX Subjects take minimum weekly dose 7.5 mg methotrexate Patients compliance problem Patients difficulty read understanding local language Patients Juvenile Idiopathic Arthritis ( JIA ) Azathioprine cyclophosphamide treatment within 6 month enter study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>